John J. Romero 2301 Pacific Ave Costa Mesa, CA 92627

January 1 through January 31, 2021

INVOICE # 080 FEDERAL MONITOR JANUARY 2021 INVOICE **TOTAL DUE \$ 19,192.83**

Duties and Responsibilities as Monitor

Generated, reviewed, and responded to emails/texts (month of January) from the Parties, Monitor Team, Court and Special Master.

Conference calls with Honorable Judge Gelpi and General Counsel

Reviewed court orders relating to the Consent Decree.

Reviewed data provided by PRPB relating to use of force re: CMR-3.

Prepared Use of Force Section of CMR-3

Reviewed and provided comments on PRPB's G.O. 100-113 Force Investigations Unit FIU.

Monitor administrative duties - reviewing Team invoices, coordinating SME work assignments

and conferring with Monitor's Office Administrative Director.

Reviewed Briefing Reports from PRPB.

Conferred with Deputy Monitor on issues relating to Monitor Office Operations

Conducted Zoom meetings with the parties and Special Master.

Conducted Zoom meetings with the Monitor Team.

Site Visit to Puerto Rico January 17 through January 22, 2021

Meetings with Secretary of DSP and new commissioner of PRPB

Meeting with Reform Unit to discuss format for Monitor's Office data request going forward

Meeting with FIU Unit re: obtain additional data relating to CMR-3.

Meetings with Monitor Team members based in Puerto Rico.

Participated in Community meeting.

Expenses January 17-22 Puerto Rico Visit

Rapid PCR Test	250.00
Airfare	327.87
Hotel	698.30
TOTAL	\$1276.17

Flat Rate Total Wages Due = \$17,916.66

Expenses Due

\$1276.17

TOTAL DUE

\$19192.83

I hereby certify that the amount billed in this invoice is true and correct in my capacity as Federal Monitor. I further certify that I have not received any income, compensation, or payment for services rendered under a regular employment or contractual relationship with the Commonwealth, or any of its departments, municipalities or agencies.

Date January 31, 2021

Case 3:12-cv-02039-FAB Document 1694-13 Filed 02/11/21 Page 3 of 6 Itinerary confirmation

Download to calendar

You're all set to jet!

Confirmation code: XITKVG

MANAGE BOOKING >

Travelers

Mr. John Joseph Romero

Flight

Ticket number

2792155987417

Frequent Flyer

JetBlue - TrueBlue - 3486580574 * *

Seat

LAX O FLL FLL O SJU SJU O MCO MCO O LAX 14D

200

30D

Checked Baggage Allowance

2 bags

2 begs

2 bags

2 bags

Your flights

Los Angeles, CA (LAX)

Sat Jan 16 2021, 10:20 PM

Fort Lauderdale, FL (FLL) Sun Jan 17 2021, 5:59 AM Flight 100 JetBlue

Fare: Blue Nonstop

A321/Mint

Fort Lauderdale, FL (FLL)

Sun Jan 17 2021, 10:50 AM

San Juan, PR (SJU) Sun Jan 17 2021, 2:17 PM Flight 253 JetBlue

Fare: Blue Nonstop

A320

San Juan, PR (SJU)

Fri Jan 22 2021, 2:50 PM

A320

Orlando, FL (MCO)

Fri Jan 22 2021, 4:51 PM

Flight 1034 JetBlue

Fare: Blue

Nonstop

Orlando, FL (MCO)

Fri Jan 22 2021, 8:30 PM

A321

Los Angeles, CA (LAX)

Fri Jan 22 2021, 11:09 PM

Flight 131

JetBlue

Fare: Blue

Nonstop

Fare breakdown

Passenger Type	Base Fare per person	Taxes & fees per person	Total Fare per person	Number of travelers	Total Fare
Adult	\$260.47	\$67.40	\$327.87	x1	\$327.87 USD

+ LAX - SJU: Blue fare rules

+ SJU - LAX: Blue fare rules



Case 3:12-cv-02039-FAB Document 1694-13 Filed 02/11/21 Page 4 of 6

COURTYARD®

Courtyard by Marriott San Juan - Miramar guest.service@courtyard.com 801 Ponce de Leon Ave. San Juan, PR. 00907 T 787,721,7400 F 787,723,0068

Mr John Romero 2301 Pacific Ave Costa Mesa CA 92627 United States

Room: 0901 Room Type: KSTE No. of Guests: 1

Rate: \$ 115.00 Clerk: 8 CRS Number 91089889

Marriott Rewards # 756834271

Name:

Arrive: 01-17-21

Time: 14:20

Depart: 01-22-21

Folio Number: 656429

Date	Description	Charges	Credits
01-17-21	Package	115.00	
01-17-21	Government Tax	10.35	
01-17-21	Hotel Fee	10.35	
01-18-21	COMEDOR- Guest Charge (Breakfast)	3.16	
01-18-21	Package	115.00	
01-18-21	Government Tax	10.35	
01-18-21	Hotel Fee	10.35	
01-19-21	COMEDOR- Guest Charge (Breakfast)	4.16	
01-19-21	Package	115.00	
01-19-21	Government Tax	10.35	
01-19-21	Hotel Fee	10.35	
01-20-21	COMEDOR- Guest Charge (Breakfast)	4.16	
01-20-21	Package	115.00	
01-20-21	Government Tax	10.35	
01-20-21	Hotel Fee	10.35	
01-21-21	COMEDOR- Guest Charge (Breakfast)	4.16	
01-21-21	Package	115.00	
01-21-21	Government Tax	10.35	
01-21-21	Hotel Fee	10.35	
01-22-21	COMEDOR- Guest Charge (Breakfast)	4.16	
01-22-21	Visa Card		698.30
	Card # XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX		

blob:https://secaste 3:12-cv-02039-FABb-Document 1694-1302 Filed 02/11/21 Page 5 of 6



7707 Garden Grove Blvd. Garden Grove, CA 92841-4207

Phone: 714-902-1762 CLIA: 05D2016898 CLF: 340712 Lab. Director: John C. Hiserodt, MD

Fax: 657-400-9073 CLIENT: 828

NEWPORT CHILDREN'S MEDICAL- NEWPO

Ordering Physician: Zacharia Reda MD

Patient Name; DOB:

Client Accn:

Accession No:

ROMERO, JOHN

6/21/1950 Age: 7

Age: 70 Gender: M

Draw Date: Receive Date: Final Report: 01/15/2021 01/15/2021 01/15/2021 Time: 14:18 Time: 17:00

Report Status: FINAL

PANEL/TEST

RESULT

ABNORMAL.

UNITS

REFERENCE RANGE

COVID-19 SARS CoV-2

2101150432

SOURCE-COVID-19 SARS-CoV2 RT-PCR Nasopharyngeal Negative

Final Result for SARS CoV-2 (COVID-19); NEGATIVE (Not Detected)

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. Optimum specimen types and timing for peak viral levels during infections caused by SARS-CoV-2 have not been determined. Collection of multiple specimens or types of specimens may be necessary to detect virus. Improper specimen collection and handling, sequence variability under primers/probes, or viruses present below the limit of detection may lead to false negative results. Positive and negative predictive values of testing are highly dependent on prevalence. False negative test are more likely results are more likely when prevalence is high.

The SARS-CoV-2 test is intended for the qualitative detection of nucleic acids from SARS-CoV-2 in nasal, nasopharyngeal and oropharyngeal swab samples from patients who meet COVID-19 clinical and/or epidemiological criteria. Testing methodology is real-time RT-PCR. The assay targets the S, N, and ORF1ab genes. If received as separate collection devices, nasal, nasopharyngeal and oro-pharyngeal specimens are combined for analysis.

Test results must be correlated with clinical presentation and evaluated in the context of other laboratory and epidemiologic data. Test performance can be affected because the epidemiology and clinical spectrum of infection caused by SARS-CoV-2 is not fully understood. For example, the optimum types of specimens to collect and when during the course of infection these specimens are most likely to contain detectable viral RNA may not be known.

This test has not been Food and Drug Administration (FDA) cleared or approved and has been authorized by FDA under an Emergency Use Authorization (EUA). The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of SARS-CoV-2 under Section 564(b)(1) of the Act, 21 U.S.C. section 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. FDA review of the validation is pending.

Pathlab Services "CLIA 05D2016898" is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. section 263a, to perform high complexity tests.

2101150432

Romero, John

Page 1 of 1

108/21. View in app or